SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (201)7/13/2001 8:03:35 PM
From: scaram(o)uche   of 1022
 
potentially eliminating the harmful immune responses that have been observed against native thrombopoietin following the administration of human thrombopoietin.

And then maybe not? I'd like them to expand on the epitopes on TP that elicit the "harmful" antibodies.

And, as always, there's the issue of immunogenicity for the new CDRs of the MAb itself.

I'm all for innovation in the field. I'm not certain that engineering is necessary, apart from the standard sort of stuff that CAT et al. could do. I presume, but do not know, that they're actually modeling the relevant structures in the "ligand of interest" and making CDR inserts that mimic them. If true, then this isn't exactly fast and easy.

A Medline for Dr. Bowdish doesn't say much apart from that she was accomplished, if a bit green, before joining industry.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News